Skip to content
    Reviews

    Updated LI-RADS Treatment Response Algorithm (v2024-2025) for Hepatocellular Carcinoma

    Sarma et alCancer Management and Research

    Updated LI-RADS Treatment Response Algorithm (v2024-2025) for Hepatocellular Carcinoma
    Hepatocellular carcinoma (HCC) management increasingly incorporates locoregional therapies, systemic agents, and modern immunotherapy combinations, resulting in complex and variable post-treatment imaging presentations that complicate the differentiation of viable residual tumor from therapy-related changes. The updated LI-RADS Treatment Response Algorithm (TRA, v2024-2025) incorporates revised guidance on arterial enhancement, washout, ancillary features, and modality-specific considerations to enhance diagnostic clarity and consistency.
    A narrative review summarizes post-treatment HCC imaging on CT, MRI, contrast-enhanced ultrasound (CEUS), dual-energy CT, and photon-counting CT; it reports that the updated LI-RADS TRA has shown potential for lesion-level assessment by clarifying criteria for defining viable, non-viable, and equivocal responses. The algorithm demonstrates high accuracy following ablation and transarterial chemoembolization (TACE); however, the review notes that ongoing refinements remain necessary for assessing responses to radiotherapy and immunotherapy.
    Advanced modalities, specifically multiparametric MRI and spectral CT, improve the identification of subtle viable tissue and help address challenging radiological confounders, including granulation tissue, perfusional alterations, and immune-related pseudo-progression. Furthermore, radiomics and machine learning models show strong potential for supporting automated viability evaluation and early recurrence prediction. Overall, the updated framework strengthens standardization across imaging modalities, with the integration of quantitative biomarkers and artificial intelligence tools positioned to support future post-treatment evaluation.

    Key Takeaways

    • The updated LI-RADS Treatment Response Algorithm (v2024-2025) demonstrates high accuracy following ablation and transarterial chemoembolization, with ongoing refinements needed for radiotherapy and immunotherapy.
    • Multiparametric MRI and spectral CT improve the detection of subtle viable tumor tissue while helping resolve confounders such as granulation tissue, perfusional changes, and immune-related pseudo-progression.
    Read the original sourceCancer Management and Research